Cadrenal Therapeutics (CVKD): PNC discloses 8.13% beneficial stake for client

Rhea-AI Filing Summary

Cadrenal Therapeutics, Inc. reports that The PNC Financial Services Group, Inc., through its subsidiary PNC Bank, National Association, holds a beneficial position in the company’s common stock.

PNC reports beneficial ownership of 233,219 shares of Cadrenal common stock, representing 8.13% of the class as of June 30, 2026. PNC has sole voting and dispositive power over these shares, with no shared voting or dispositive power. The shares are held in a fiduciary account at PNC Bank for a client, identified as Daniel Maltz, who has the right to receive dividends and sale proceeds from this more-than-5% position.

Key Figures

Beneficially owned shares: 233,219 shares Percent of class: 8.13% Sole voting power: 233,219 shares +2 more

5 metrics

Beneficially owned shares 233,219 shares Cadrenal Therapeutics common stock beneficially owned by PNC as of June 30, 2026

Percent of class 8.13% Portion of Cadrenal Therapeutics common stock class beneficially owned by PNC

Sole voting power 233,219 shares Shares over which PNC has sole power to vote or direct the vote

Sole dispositive power 233,219 shares Shares over which PNC has sole power to dispose or direct disposition

Record owner client threshold more than five percent Client Daniel Maltz has rights to dividends and proceeds on a >5% position

Key Terms

beneficially owned, sole voting power, sole dispositive power, fiduciary capacity, +1 more

5 terms

beneficially owned financial

"Item 4. | Ownership (a) | Amount beneficially owned: 233,219"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

sole voting power financial

"Sole Voting Power 233,219.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

sole dispositive power financial

"Sole Dispositive Power 233,219.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

fiduciary capacity financial

"held in an account at PNC Bank, National Association in a fiduciary capacity"

parent holding company financial

"Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/07/2026 - 08:12 AM Accepted by SEC EDGAR 08/07/2026 - 08:11 AM Learn about SEC filing dates

FAQ

What percentage of Cadrenal Therapeutics (CVKD) does PNC beneficially own?

The PNC Financial Services Group, Inc. reports beneficial ownership of 8.13% of Cadrenal Therapeutics’ common stock, representing a significant institutional position in the company as of June 30, 2026.

How many Cadrenal Therapeutics (CVKD) shares are reported as beneficially owned?

PNC reports beneficial ownership of 233,219 shares of Cadrenal Therapeutics common stock, over which it has sole voting and sole dispositive power through its banking subsidiary.

Who ultimately benefits from PNC’s Cadrenal Therapeutics (CVKD) holdings?

The shares are held in a fiduciary account at PNC Bank, National Association for a client, Daniel Maltz, who has rights to dividends and sale proceeds on this more-than-5% position.

Does PNC share voting or dispositive power over Cadrenal Therapeutics (CVKD) shares?

No. PNC reports sole voting power and sole dispositive power over all 233,219 Cadrenal Therapeutics shares and no shared voting or dispositive power with any other party.

Which PNC subsidiary holds the Cadrenal Therapeutics (CVKD) shares?

The shares are held by PNC Bank, National Association, a subsidiary of The PNC Financial Services Group, Inc., in a fiduciary capacity for the client identified in the disclosure.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Cadrenal Therapeutics, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

127636207

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 127636207

1

Names of Reporting Persons

The PNC Financial Services Group, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

PENNSYLVANIA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 233,219.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 233,219.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

233,219.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.13 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Cadrenal Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 822 A1A North, Suite 306, Pontre Vedra, FL 32082
Item 2.
(a)	Name of person filing: The PNC Financial Services Group, Inc.
(b)	Address or principal business office or, if none, residence: 300 Fifth Avenue, Pittsburgh, PA 15222-2401
(c)	Citizenship: Pennsylvania
(d)	Title of class of securities: Common Stock
(e)	CUSIP Number(s): 127636207
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 233,219
(b)	Percent of class: 8.13 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 233,219
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 233,219
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. The securities as to which this Schedule is filed are owned of record by a client of the subsidiary identified in Item 7. The client has the right to receive, or the power to direct the receipt of, dividends from, or the proceeds from the sale of, such securities. Such client is known to have such right or power with respect to more than five percent of this class of securities: Daniel Maltz.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. PNC Bank, National Association - BK The total shares reported herein are held in an account at PNC Bank, National Association in a fiduciary capacity for the client noted in Item 6.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

The PNC Financial Services Group, Inc.

Signature:	Gregory H. Kozich
Name/Title:	Senior Vice President & Controller
Date:	08/07/2026